DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20174729

Idiopathic acute onset pulmonary artery hypertension in infancy need for research

Sangeeta V. B., Adarsh E., Divya N., Amrutha S.

Abstract


Background: The aim of this study was to study the clinical outcome of infants beyond neonatal period who presented with acute onset pulmonary artery hypertension of unknown etiology.

Methods: This is a retrospective case record analysis of all the babies admitted to pediatric intensive care unit between January 2013 to March 2017 at Rajarajeswari Medical College with signs and symptoms of Pulmonary Arterial Hypertension on clinical examination and ECHO. Descriptive and inferential statistical analysis has been carried out in the present study.

Results: Out of 49 infants beyond neonatal period who presented with Pulmonary Arterial Hypertension, 9 were females and 40 were males. 43 babies required ventilator support and 6 babies required only supplemental oxygen. Out of 33 babies who expired, cardiogenic shock and severe hypoxia was the main cause of death in 19, pulmonary hemorrhage in 4, acute kidney injury and fluid overload in 2, multi organ dysfunction in 1, septicemia in 4 and disseminated intravascular coagulation in 3. Babies who survived less than 72 hours cardiogenic shock and severe hypoxia was the main cause of death and babies who survived more than a week, pulmonary hemorrhage, acute kidney injury and fluid overload, multi organ dysfunction, septicemia and disseminated intravascular coagulation were the main cause of death.

Conclusions: There is a need for research in infants beyond neonatal period with pulmonary arterial hypertension, to find out the etiology.


Keywords


Infancy, PAH, Unknown etiology

Full Text:

PDF

References


Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension: N Engl J Med. 1992;327:76-81.

Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin: Ann Intern Med. 1994;121 409-15.

Yam S, Wagenvoort CA. Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients: Br Heart J. 1985;54:428-34.

Sandoval J, Bauerle O, Gomez A, Palomar A, Martinez Guerra ML, Furuya ME. Primary pulmonary hypertension in children: clinical characterization and survival: J Am Coll Cardiol. 1995;25:466-74.

D’Alonzo GE, Barst RJ, Ayres SM. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med. 1991;115:343-49.

Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathological study of the lung vessels in 156 clinically diagnosed cases. Circ. 1970;42:1163-84.

Barst RJ. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest. 1986;89:497-503.

Rich S, Brundage BH. High-dose calcium channel blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy: Circ. 1987;76:135-41.

Barst RJ, Stalcup SA, Steeg CN, Hall JC, Frosolono MF, Cato AE, et al. Relation of arachidonate metabolites in abnormal control of the pulmonary circulation in a child: Am Rev Respir Dis. 1985;131:171-7.

Giaid A, Saleh D. Reduced expression of nitric oxide synthase in the lungs of patients with pulmonary hypertension: N Engl J Med. 1995;333:214-21.

Rao SN, Chandak GR. Cardiac beriberi often a missed diagnosis. J Tropical Pediatr. 2010;56(4):2010.